mTOR inhibitors in the management of hormone receptor-positive breast cancer: The latest evidence and future directions

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2526-2535

  Villarreal garza, C ^a   Cortes, J ^b   Andre, F ^c   Verma, S ^d  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Breast cancer; Endocrine resistance; Everolimus; MTOR inhibitors; Temsirolimus

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS;

ARTICLE; BREAST METASTASIS; CANCER GROWTH; CANCER STAGING; CELL SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; INTERSTITIAL PNEUMONIA; LOADING DRUG DOSE; LUNG FUNCTION TEST; METABOLIC DISORDER; OXYGEN SATURATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT RESPONSE;

EID: 84867138398     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds075     Document Type: Article

References (64)

1. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2005; 23: 1609-1610.
2. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
3. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008; 26: 798-805.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
5. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
6. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
7. Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22Suppl 6vi12-vi24.
8. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. http://www.nccn.org/professionals/physician_gls/pdf/ breast.pdf (9 December 2011, date last accessed).
10. Rodriguez Lajusticia L, Martin Jimenez M, Lopez-Tarruella Cobo S. Endocrine therapy of metastatic breast cancer. Clin Transl Oncol 2008; 10: 462-467.
11. Thurlimann B, Hess D, Koberle D et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85: 247-254.
12. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
13. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
14. Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003; 26: 317-322.
15. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007; 105 (Suppl 1): 19-29.
16. Paridaens RJ, Dirix LY, Beex LV et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 4883-4890.
17. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98: 1285-1291.
18. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009; (4): CD003370.
19. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, doubleblind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
20. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600.
21. Robertson JFR, Lindemann JPO, Llombart-Cussac A et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study. Cancer Res 2011; 70: S1-S3; (Abstr S1-3).
22. Lonning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer 2009; 45: 527-535.
23. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471-477.
24. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236-239.
25. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
26. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
27. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptorpositive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664-1670.
28. Schiff R, Massarweh SA, Shou J et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10: 331S-336S.
29. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233-247.
30. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-233.
31. Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. Breast Cancer Res Treat 2011; 128: 599-606.
32. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
33. Wu G, Xing M, Mambo E et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7: R609-616.
34. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
35. deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10: 8059-8067.
36. Beeram M, Tan QT, Tekmal RR et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18: 1323-1328.
37. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11: 5319-5328.
38. Macaskill EJ, Bartlett JM, Sabine VS et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2011; 128: 725-734.
39. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637.
40. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
41. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
42. Baselga J, Roche H, Fumoleau P. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res Treat 2005; 94 (Suppl 1): S62.
43. Chow L, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100: 6091.
44. Bachelot T, Bourgier C, Cropet C et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone receptor-positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase Inhibitors (AI). Cancer Research 2011; 70: S1-S6; (Abstr S1-6).
45. Bourgier C, Coquard R, Provencal J et al. Exploratory subgroup analysis of the TAMRAD Phase 2 GINECO Trial comparing tamoxifen (TAM) plus everolimus (RAD) with TAM alone in patients with hormone-receptor-positive, HER2-negative metastatic breast cancer (mBC) with prior exposure to aromatase inhibitors (AIs): implication for research strategies. In 2011 European Multidiscliplinary Cancer Congress, Edition Stockholm, Sweden: 2011.
46. Bhattacharyya GS, Biswas J, Singh JK et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. In 2011 European Multidiscliplinary Cancer Congress, Edition Stockholm, Sweden: 2011.
47. Baselga J, Campone M, Sahmoud T et al. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 Phase III Trial. In 2011 European Multidiscliplinary Cancer Congress, Edition Stockholm, Sweden: 2011.
48. Hortobagyi GN, Piccart M, Rugo H et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III Trial. In 2011 San Antonio Breast Cancer Symposium, Edition San Antonio, US: 2011.
49. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366(6) 520-529.
50. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
51. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
52. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008; 44: 2781-2790.
53. Johnson SRD. Role of the mTOR Pathway in Endocrine-Resistant Breast Cancer-Opportunities for Novel Combination Strategies. 2009 American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology.
54. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128.
55. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
56. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
57. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
58. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
59. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-1298.
60. Stokman MA, Spijkervet FK, Boezen HM et al. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of metaanalyses. J Dent Res 2006; 85: 690-700.
61. Potting CM, Uitterhoeve R, Op Reimer WS, Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur J Cancer Care (Engl) 2006; 15: 431-439.
62. Ellard SL, Clemons M, Gelmon KA et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
63. Kennecke H, McArthur H, Olivotto IA et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 2008; 112: 1437-1444.
64. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.